Gore Range Capital

Or-Genix Therapeutics, Inc., an early stage therapeutics company, develops prescription and non-prescription products to treat skin, hair, and mucous membrane disorders. The company’s portfolio includes molecular compounds for multiple dermatological and cosmetics indications, including hormonal acne, excess skin oiliness, menopause related hair thinning, senile vaginitis, hormonally-aged skin, and post-surgical tissue necrosis. The company was founded in 2015 and is based in Worcester, Massachusetts.

CoreMedica Laboratories Inc. develops blood serum separation and transportation containers for screenings. It serves corporate wellness, epidemiological research, pharma, clinical trials monitoring, and insurance underwriting industries. CoreMedica Laboratories Inc. was founded in 2010 and is based in Lee's Summit, Missouri.

Eirion Therapeutics is a clinical-stage biopharmaceutical company that is developing next-generation prescription products for aesthetic dermatology. The company currently has a rich pipeline of products focusing on treatments for wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. In the future, Eirion plans to also pursue additional indications that address other major unmet clinical needs for physicians and their patients.

Dorsata enables healthcare providers to make better decisions that are informed by data and best practices. The company provides teams of clinicians tools to build, share, and then use defined workflows, called care pathways, for efficient decision-making, documentation, and order entry. Leveraging these clinician-developed care pathways, Dorsata is committed to transforming healthcare from a cost-reduction and quality improvement standpoint. Dorsata was founded in 2011 and is headquartered in Washington, District of Columbia, United States.

Paradigm Diagnostics, Inc. provides diagnostics and biomarker driven clinical trial services for cancer patients. The company offers PCDx test that provides patients and physicians with a blueprint of the underlying mechanisms of a patient’s disease, potential treatment approaches, and inventory of relevant clinical trials, as well as assesses clinically-actionable genomic variations in cancer, including mutations, copy number variations, mRNA expression, and protein expression. It also offers BioPharma services, which include personalized clinical trial assays, biorepository consultation, molecular services, nucleic acid isolation, and laser capture enrichment, as well as bio specimen collection, storage, processing, and analysis services. The company was founded in 2012 and is based in Phoenix, Arizona. As of March 3, 2020, Paradigm Diagnostics, Inc. operates as a subsidiary of Exact Sciences Corporation.

Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic and proteomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of the patient’s tumor; thus, personalizing each patient’s course of treatment.

Claret Medical, Inc. develops a series of cerebral vascular protection systems for transcatheter aortic valve implantation, surgical, and other interventional procedures. The company’s products include Claret Medical Montage, a dual filter system and percutaneously delivered embolic protection device to capture and remove debris disloged during vascular procedures; and small (6F) catheters that are inserted into the patient's right arm to protect the patient’s brain during interventional procedures where embolic debris might be released. It offers its products for use as an embolic protection system to capture and remove embolic material (thrombus/debris) that may enter the cerebral vascular system during endovascular procedures. The company was incorporated in 2009 and is based in Santa Rosa, California.

AOA based in Boston, New York, and London developing cancer diagnostics in the field of women’s health.AOA is a female-led company, is committed to bringing the first accurate early-stage liquid biopsy ovarian cancer diagnostic test to market that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers.

NovaScan, Inc. manufactures and develops cancer detection devices. Its device uses Cole relaxation frequency for cancer detection and stratification. The company offers MarginScan, a device for detecting skin cancers; BiopsyScan, a device enabling breast biopsy; FastScan Probe, a device that detects the presence of breast cancer; as well as electrical mammogram and platform technology for the detection of multiple cancerous conditions. NovaScan, Inc. was formerly known as EPET, LLC. The company was incorporated in 2001 and is based in Chicago, Illinois.

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.

Castle Biosciences, we focus on addressing this gap. We work with leading cancer institutions to in-license proprietary technologies and complete development and validation. The ultimate goal is to make these proven tests available to all individuals afflicted with a rare cancer.

xMD Diagnostics operates in the healthcare industry focusing on biotechnology business. The company was formerly known as Bay Resources Development Group. The company is headquartered in Annapolis, Maryland. xMD Diagnostics uses high-throughput microdissection technology for the diagnosis of cancer.

Medikly, Inc. provides a digital marketing platform for healthcare marketers. Its digital marketing platform enables marketers to capture and apply actionable physician intelligence. The company also provides MediklyOS, a solution that enables brands to launch, execute, modify, and measure marketing campaigns; and consulting, support, training, integration, and campaign services. Medikly, Inc. was founded in 2009 and is based in Jersey City, New Jersey.

Conversa enables health systems to virtually engage, monitor and manage patients for chronic care, acute discharge, perioperative, oncology, OBGYN, prevention and wellness, and more. The automated care platform engages patients at high frequency and scale, while triaging to care venues when necessary, optimizing and improving the use of telehealth e-visits, phone calls and in-person consults. Conversa’s suite of COVID-19 Virtual Care Programs is being used by innovative organizations like UCSF Health, Northwell, UNC Health, Prisma Health and University Hospitals to provide symptom checking and triage, provide check-ins with quarantined patients, deliver lab results and screen employees, patients and visitors.

Dorsata enables healthcare providers to make better decisions that are informed by data and best practices. The company provides teams of clinicians tools to build, share, and then use defined workflows, called care pathways, for efficient decision-making, documentation, and order entry. Leveraging these clinician-developed care pathways, Dorsata is committed to transforming healthcare from a cost-reduction and quality improvement standpoint. Dorsata was founded in 2011 and is headquartered in Washington, District of Columbia, United States.

Dorsata enables healthcare providers to make better decisions that are informed by data and best practices. The company provides teams of clinicians tools to build, share, and then use defined workflows, called care pathways, for efficient decision-making, documentation, and order entry. Leveraging these clinician-developed care pathways, Dorsata is committed to transforming healthcare from a cost-reduction and quality improvement standpoint. Dorsata was founded in 2011 and is headquartered in Washington, District of Columbia, United States.

Validic is the healthcare industry's premier technology platform for convenient, easy data access to a world of mobile health and in-home devices, fitness equipment, clinical sensors, activity wearables, smart bands, and wellness applications. Founded in 2010, Validic is headquartered in Durham, North Carolina.

Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.